

2 **Dysbiosis in metabolic genes of the gut microbiomes of patients with an ileo-anal pouch resembles that observed in Crohn's Disease**

4 **Authors:**

6 Vadim Dubinsky¹, Leah Reshef¹, Keren Rabinowitz^{2,3}, Karin Yadgar^{2,3}, Lihi Godny^{2,3}, Keren Zonensain^{2,3}, Nir Wasserberg^{4,5}, Iris Dotan^{2,4*}, Uri Gophna^{1*}

8 **Affiliation:**

10 ¹The Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel-Aviv University, Tel Aviv, Israel.

²The Division of Gastroenterology, Rabin Medical Center, Petah-Tikva, Israel.

12 ³Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva, Israel.

⁴Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.

14 ⁵Colorectal Unit, the Division of Surgery, Rabin Medical Center, Petah-Tikva, Israel.

16 * Correspondence to urigo@tauex.tau.ac.il; irisdo@clalit.org.il

18

20

22

24

26

28

2

30 Abstract

32 Background

34 Crohn's disease (CD), ulcerative colitis (UC) and pouchitis are multifactorial and chronic inflammatory
36 diseases of the gastrointestinal tract, termed together as inflammatory bowel diseases (IBD). Pouchitis
38 develops in former patients with UC after total proctocolectomy and ileal pouch-anal anastomosis
40 ("pouch surgery") and is characterized by inflammation of the previously normal small intestine
comprising the pouch. It has been extensively shown that broad taxonomic and functional alterations
("dysbiosis") occur in the gut microbiome of patients with IBD. However, the extent to which
microbial dysbiosis in pouchitis resembles that of CD or UC has not been investigated in-depth, and the
pathogenesis of pouchitis largely remains unknown.

Results

42 In this study we collected 250 fecal metagenomes from 75 patients with a pouch, including both non-
44 inflamed (normal pouch) and inflamed (pouchitis) phenotypes, and compared them to publicly
46 available metagenomes of patients with CD (n=88), and UC (n=76), as well as healthy controls (n=56).
48 Patients with pouchitis presented the highest level of dysbiosis compared to other IBD phenotypes
50 based on species, metabolic pathways and enzyme profiles, and their level of dysbiosis was correlated
52 with intestinal inflammation. In patients with pouchitis, the microbiome mucin degradation potential
54 was lower, but was accompanied by an enrichment of *Ruminococcus gnavus* strains encoding specific
mucin-degrading glycoside hydrolases, which might be pro-inflammatory. Butyrate and secondary bile
acids producers were decreased in all IBD phenotypes and were especially low in pouchitis. Butyrate
synthesis genes were positively correlated with total dietary fiber intake. Patients with pouchitis
harbored more facultative anaerobic bacteria encoding enzymes involved in oxidative stress response,
suggesting high oxidative stress during pouch inflammation. Finally, we have developed enzymes-
based classifiers that can distinguish between patients with a normal pouch and pouchitis with an area
under the curve of 0.91.

56 Conclusions

58 We propose that the non-inflamed pouch is already dysbiotic (function- and species-wise) and
60 microbially is more similar to CD than to UC. Our study reveals microbial functions that underlie the
62 pathogenesis of pouchitis and suggests bacterial groups and functions that could be targeted for
nutritional intervention to attenuate or prevent small intestinal inflammation present in pouchitis and
CD.

Keywords: Pouchitis, UC, CD, mucin, butyrate, bile acids, oxidative stress, classifier.

64

66

68 Background

70 Inflammatory bowel diseases (IBD), including Crohn's disease (CD), ulcerative colitis (UC) and
71 pouchitis, are chronic, relapsing and remitting inflammatory conditions of the intestine. CD mainly
72 affects the small intestine and colon, while UC is localized in the colon. The etiology of IBD is
73 multifactorial, involving genetic predisposition [1], environmental triggers [2], and an aberrant
74 immune-mediated response towards specific antigens of the intestinal microbiota [3].

75 Approximately 25% of patients with complicated UC may undergo total large bowel resection.
76 Reconstruction of intestinal continuity is achieved by the creation of a reservoir ("pouch") from the
77 healthy small intestine which is connected to the anus (ileal pouch-anal anastomosis, "pouch surgery")
78 [4]. Up to 60% of these former UC patients may develop inflammation of the previously normal small
79 intestine comprising the pouch (pouchitis) [5]. Pouchitis is the most common complication after pouch
80 surgery, but its pathogenesis is still largely unknown [6].

81 It has been previously shown that the gut microbiome in patients with IBD is characterized by
82 lower diversity, lower stability and compositional changes in specific taxa compared to healthy
83 individuals [7]. Levels of facultative anaerobes from *Enterobacteriaceae* are increased while beneficial
84 obligate anaerobes such as *Faecalibacterium prausnitzii* and *Eubacterium rectale* are decreased [8, 9,
85 10, 11, 12]. Shifts in microbial functions in the metagenomes of patients with IBD had also been
86 demonstrated, e.g. lower presence of short-chain fatty acid (SCFA) synthesis pathways, increase in
87 oxidative stress response genes, and alteration in amino-acids metabolism genes [9, 13]. These
88 taxonomic and functional changes are broadly referred to as "dysbiosis".

89 We had previously demonstrated that patients with a pouch and CD might have several
90 mechanisms of pathogenesis in common including mucosal gene and microRNA expression [14, 15],
91 anti-glycan serologic responses [16], and CD-like bacterial dysbiosis [11]. Yet, the extent to which
92 microbial dysbiosis in pouchitis resembles that of CD has not been investigated in depth. Here we
93 analyzed the shotgun metagenomes of patients with a pouch, IBD and healthy subjects with the
94 following aims: 1) To identify microbial signatures (species and functional genes) that might be
95 common to disease phenotypes and thus to place patients with a pouch in the context of "primary" IBD.
96 More specifically, we wanted to test whether pouchitis has microbial features that are more similar to
97 those of CD. 2) To examine several key bacterial functions that may underlie the pathogenesis of
98 pouchitis: excessive mucin degradation, reduced butyrate and secondary bile acids production, and
99 increased bacterial resistance to oxidative stress.

100

Methods

102 Study cohorts description and metadata characteristics

103 Patients after pouch surgery were recruited at a dedicated pouch clinic in a tertiary IBD referral center
104 in Israel (Rabin Medical Center [RMC]). The study was approved by the local institutional review
105 board (0298–17) and the National Institutes of Health (NCT01266538). Demographic and clinical data
106 were obtained during clinic visits. After signing informed consent, patients were followed
107 prospectively, and clinic visits including fecal sample collection were scheduled every 3 months or
108 when patients had an episode of pouchitis. Fecal samples were collected in sterile cups and
109 immediately frozen at -80°C until processing. Fecal calprotectin levels were measured. Pouch disease
110 behavior (phenotype) was defined as normal pouch, acute/recurrent-acute pouchitis, chronic pouchitis
111 or Crohn's like disease of the pouch (CLDP); see Supplementary Materials and Methods for a detailed

112 description. Disease activity was defined based on global physician assessment and on the clinical
113 subscore of the pouchitis disease activity index [17].

114 For the exploratory analysis done in this study, the patients were divided into two groups
(discovery cohort): normal pouch (n=35, 103 fecal samples) and pouchitis (n=34, 105 fecal samples).
116 Normal pouch group included samples from patients with a normal pouch (with UC or familial
adenomatous polyposis [FAP] background), while the pouchitis group included samples from patients
118 with chronic pouchitis and CLDP. Samples from patients with recurrent-acute pouchitis phenotype
were set aside for testing the pouchitis prediction classifier (validation cohort; see Machine learning
120 classifiers part). For these patients, the clinical phenotype defined during the last follow-up clinic visit
was recorded. In the validation cohort, 42 samples from 19 patients were included and owing to the
122 longitudinal nature of the cohort, 13 of these patients had also a sample in the discovery cohort which
were treated independently. For dietary fiber information obtained for a subset of 52 samples, see
124 Supplementary Materials and Methods.

We excluded samples collected during or within 1-month of antibiotics treatment. 84% of the
126 pouch samples in our dataset were off-antibiotics for 180 days or longer and the rest were off-
antibiotics between 1 to 6-months (Supplementary Table 1A, B). While patients with pouchitis tend to
128 have a history of high antibiotic use, after 1-month off antibiotics, the microbiome diversity is
significantly increased, and following 6-months post-antibiotics it recovers to pre-treatment levels [12].
130 Nevertheless, to account for any remaining confounding antibiotics effects, we also included antibiotic
use (1-month or 6-months without antibiotics) as a covariate in the models.

132 Non-pouch IBD (patients with UC and CD) and healthy adult metagenomes were obtained from
publicly available data, previously published in [18], and are part of the PRISM, LifeLines DEEP and
134 NLIBD cohorts. We analyzed these metagenomes with the same bioinformatic pipeline as the pouch
metagenomes as described in the following sections, starting the analysis from raw reads.

136

DNA Extraction and Shotgun Metagenomic Sequencing of Pouch Samples

138 DNA was extracted from fecal samples as described in [11]. Genomic libraries were prepared with the
Nextera XT library preparation kit using approximately 1 ng of total DNA per sample (DNA
140 concentrations verified by Qubit fluorometry). Metagenomic sequencing was done using Illumina (San
Diego, CA) NextSeq500 paired-end (2 x 150 base pair reads) at DNA Services Facility, University of
142 Illinois, Chicago, IL. Sequencing reads were quality filtered with Trimmomatic v0.36 [19] using
default parameters, thus removing low-quality and short reads, low-quality bases, and clipping Illumina
144 adaptors. Human host DNA reads were removed by mapping metagenomic reads against the GRCh38
human genome (build 38) with Bowtie2 version-2.2.9 [20] in *--very-sensitive-local* mode. After reads
146 trimming and human reads removal, the mean sequence depth (\pm standard deviation) was 0.93 ± 0.3
Gbp (6.22 ± 2 million reads) per sample.

148

Taxonomic and functional profiling of the metagenomic datasets

150 Taxonomic profiling was performed using MetaPhlAn2 classifier v2.6.0 [21] which classifies
metagenomic reads by mapping to a database of clade-specific marker genes. MetaPhlAn2 was run
152 with the following parameters changed from default: *--tax_lev* set to "s" (classify taxonomy to species
level), *--ignore_virus*, and *--ignore_eukaryotes* to ignore viral and eukaryote reads, respectively.
154 Species relative abundance tables from all samples were merged. Species present in less than 5% of the
samples and at less than 0.1% relative abundance in any individual sample were removed. For all
156 downstream statistical analysis, we used the bacterial species that are common to the pouch and non-

pouch metagenomes (species intersection). This procedure can minimize potential confounders such as species that appear solely in one dataset due to country-specific differences. The only exception was for the Shannon diversity index calculation, where all taxa (union) from both datasets were used in order to obtain a more complete and accurate diversity trend.

Functional profiling was performed with HUMAnN2 v0.11.1 [22]. Briefly, HUMAnN2 first maps metagenomic reads (nucleotide-level with Bowtie2) against functionally annotated pangenomes of the species identified during taxonomic profiling. Reads that do not map to any identified pangenome are subjected to a translated search with DIAMOND [23] against the UniRef90 protein database, and hits are weighted according to alignment quality, sequence length, and coverage. Gene-level outputs are produced in reads per kilobase units and stratified according to known/unclassified microbiome contributions. Per-sample gene abundances were total-sum scaled normalized (to account for the number of reads in each metagenome) to copies per million (cpm) units. The obtained gene abundances were regrouped to MetaCyc metabolic pathways and enzymes (Enzyme Commission number [EC]).

172 **Screening the metagenomes for key bacterial functions with custom curated databases**

For the identification and quantification of butyrate synthesis pathways, an extensive database from [24] was used, which encompassed hidden Markov models (HMM) on full length proteins considering the entire taxonomic diversity of butyrate producers that contained 1,716 genomes. A modified version of this database was used so that only four terminal enzymes in the main pathways known for butyrate production from each of the genomes were considered: in both acetyl-CoA and glutarate pathways, the terminal enzymes are butyryl-CoA:acetate CoA transferase (*but*) and butyrate kinase (*buk*). In 4-aminobutyrate pathway, the terminal enzyme is butyryl-CoA:4-hydroxybutyrate CoA transferase (*4hbt*), and in lysine pathway, the terminal enzyme is butyryl-CoA:acetoacetate CoA transferase (*ato*). For the analysis of microbiome-derived secondary bile acids, we used the database from [25], which was built on the full length HMM for the *bai* genes cluster (*baiA-I* operon) that consisted of *baiA*, *baiB*, *baiCD*, *baiE*, *baiF*, *baiG*, *baiH*, *baiI* genes, obtained from all genomes available in PATRIC.

Quality-filtered metagenomic reads were used as a query in a translated nucleotide search (BLASTX using DIAMOND v0.9.24.125 [23]) against the databases described above. Only the top hit per read was reported (*--max-target-seqs* 1) and the minimum e-value threshold was set to 1×10^{-5} (*--evalue*). For butyrate synthesis genes, only reads with sequence similarity matches of $\geq 90\%$ to a reference, and ≥ 25 amino acids alignment length were retained and counted. For bacterial secondary bile acid production genes, the sequence similarity cutoff was lowered to $\geq 70\%$ due to a less comprehensive reference database. Read counts for each of the key functions analyzed (butyrate and secondary bile acids genes) were normalized to RPKM units (Reads per kilobase per million mapped reads), i.e. normalized according to the corresponding median gene length and total-sum scaled according to the number of reads in each metagenome. The key functional genes were assigned to bacterial taxa according to the taxonomic identity of the respective gene entries in the database.

196 **Mucin degradation glycoside hydrolases (GH) enzymes analysis**

For the analysis of glycoside hydrolases (GH) enzymes that are involved in mucin degradation, only GH that were functionally characterized by *in-vitro* activity or transcriptomic assays [26] were considered. Thus the following enzymes from HUMAnN2 EC4 annotations were considered as mucin-

200 related GH: Protein O-GlcNAcase (EC 3.2.1.169), Exo-alpha-sialidase (EC 3.2.1.18), Beta-
galactosidase (EC 3.2.1.23), Alpha-N-acetylgalactosaminidase (EC 3.2.1.49), Alpha-N-
202 acetylglucosaminidase (EC 3.2.1.50), Alpha-L-fucosidase (EC 3.2.1.51) and Beta-N-
acetylhexosaminidase (EC 3.2.1.52).

204 To analyze the specific GH of *Ruminococcus gnavus*, GH29 (Alpha-L-fucosidase), GH95
(glycoside hydrolase family 95) and GH33 (Exo-alpha-sialidase) protein sequences of *Ruminococcus*
206 *gnavus* ATCC 29149 strain JCM6515 were downloaded from Carbohydrate-Active enZymes (CAZY)
database [27]. Three single-copy housekeeping genes (DNA gyrase subunit A [*gyrA*], recombinase A
208 [*recA*], and 50S ribosomal protein L2 [*rplB*]) of the same *R. gnavus* strain were downloaded as well.
These GH and the housekeeping genes were used to build a reference database for similarity search as
210 mentioned previously. For GH, sequence similarity matches of $\geq 90\%$ and ≥ 25 amino acids alignment
length were used, and for housekeeping genes, sequence similarity matches were increased to $\geq 97\%$ to
212 count only closely related species. Read counts were normalized by the corresponding gene length, and
the percentage of *R. gnavus* strains encoding GH29, GH95 and GH33 were calculated by dividing each
214 GH by the mean abundance of *gyrA*, *recA*, and *rplB*. As *gyrA* recruited the highest number of reads
even after gene-length normalization, we used only *gyrA* for the final calculation. Samples with fewer
216 than 5 *gyrA* reads of *R. gnavus* were removed from the analysis.

218 **Statistical analysis**

The Kruskal-Wallis H-test with Dunn's test for multiple comparisons correction (pairwise tests
220 between phenotypes) was performed using *kruskal.test* and *dunn.test* functions in R package
'dunn.test'. Alpha-diversity (within-sample) was calculated with the Shannon diversity index using
222 *diversity* function in R package 'vegan'. Beta-diversity (between-sample) was calculated with Bray-
Curtis dissimilarity (*vegdist* function in R package 'vegan') and visualized with principal coordinate
224 analysis *cmdscale* function (classical multidimensional scaling) in R. Spearman rank correlation
between the first axis of microbiome variation, Shannon diversity, and key functional genes and fecal
226 calprotectin was performed using *cor.test* function in R.

To calculate the proportion of variance explained by each tested variable on Bray-Curtis
228 dissimilarity (for species, pathways and enzymes), permutational multivariate analysis of variance
(PERMANOVA) test was performed using *adonis* function in the R package 'vegan'. The variables
230 included disease phenotype, age, antibiotic use, fecal calprotectin, gender, disease activity, pouch
phenotype and inter-subject variation (the last four variables were only available for the cohort of
232 patients with a pouch and were fitted separately). The variance explained by each variable was
calculated independently of other variables to avoid issues related to variable ordering.

234 To test for differently abundant microbiome features (species, enzymes, and pathways profiles)
in different IBD phenotypes, generalized linear mixed-effects models from the R package MaAsLin2
236 v0.99.12 (<http://huttenhower.sph.harvard.edu/maaslin>) were used. Bacterial taxonomy and gene relative
abundance data were log-transformed and additive smoothing of minimum non-zero values was applied
238 to zero values on a per-sample basis. The transformed abundances were modeled as a function of IBD
phenotype (healthy subjects as the reference point), while adjusting for age and antibiotic use (fixed
240 effects). For antibiotic use, a time window of 1-month (recent use) or 6-months off antibiotics was
used. To account for the longitudinal dataset of pouch patients (repeated measurements), individual
242 patients from which a set of samples were derived, were specified as a random effect (patient ID). To
account for potential confounders due to the combination of several cohorts of patients, the cohort from
244 which each sample was derived was specified as another random effect (cohort ID). All reported P

values were adjusted for multiple hypotheses testing using the Benjamini-Hochberg method. For
246 differential abundance analysis of key bacterial genes (*but*, *buk*, *atoAD*, *4hbt* and *bai* genes cluster) in
IBD phenotypes, a linear mixed-effects model was used with the same fixed and random effects as
248 described above, with *lmer* function from the R package ‘lme4’.

250 ***Machine learning classifiers***

Profiles of bacterial species, metabolic pathways, and enzymes composition were used to build
252 classification models to distinguish between pouch phenotypes (normal pouch vs. pouchitis). The
machine-learning algorithm of gradient boosting trees (GBT) was used, as implemented in Python
254 package XGBoost (eXtreme Gradient Boosting [28]) with *XGBClassifier* function. The best
hyperparameters were tuned empirically using grid search matrix (*GridSearchCV* function in Python
256 “scikit-learn” package). Briefly, learning rate = 0.025, number of boosted trees = 500 (*n_estimators*),
each tree was constructed randomly with 50% of the features (*colsample_bytree*) and trained randomly
258 on 50% of the samples (*subsample*) and a maximum depth of a tree = 3 (*max_depth*). The rest of the
classifier parameters were left as in default (unchanged). The GBT classifiers were trained and
260 evaluated on the discovery cohort (pouch samples from the normal pouch and pouchitis groups) by
using five-fold cross-validation (randomly repeated 100 times) with *StratifiedKfold* function (“scikit-
262 learn” package), that preserves the same distribution of classes in each fold as in the complete training
set. The classifier was tested on the validation cohort of patients with recurrent-acute pouchitis, to test
264 its ability to correctly predict whether these patients will become normal pouch or pouchitis in future
follow-up (the true label was the phenotype defined during the last follow-up clinic visit). The model
266 performance was assessed by calculation area under the curve (AUC), sensitivity, specificity, and
accuracy metrics.

268 To improve the model’s predictive power (considering only the most informative features) and
reduce complexity (reducing the feature space by removing uninformative and co-correlated features),
270 feature importance scores were computed using the internal XGBoost function (*feature_importances_*),
which assigns a score to each feature used in the decision tree during model training. The average
272 feature importance scores for each model (species, pathways and enzymes) were calculated by
considering the mean score of each feature for each fold across the repeated (x100) five-fold cross-
274 validation.

276 ***Availability of data and materials***

All the metagenomic sequence data generated and used in this study (patients with a pouch) have been
278 deposited in NCBI SRA and is available under BioProject number PRJNA637365. This study also used
our previously published sequence data from PRJNA524170. Metagenomes from patients with UC, CD
280 and healthy controls were obtained from PRJNA400072. Analysis scripts with code for the machine
learning classifiers are available in the GitHub repository
282 (https://github.com/VadimDu/pouchitis_classifiers).

284 **Results and discussion**

We enrolled 75 patients with a pouch in this study; the median age was 43.8 (interquartile range 33.8-
286 62.2), and 60% were males (Supplementary Table 1A, B). 250 fecal samples were collected
longitudinally (median of 3 samples per patient) over a period of up to 5.8 years. Based on our

288 classification system (Materials and Methods), these patients were divided into two main groups that
289 were used throughout most analysis (discovery cohort): patients with a normal pouch (non-inflamed;
290 n=35) and pouchitis (inflamed; n=34). The normal pouch and pouchitis groups consisted of 103 and
291 105 samples, respectively. An additional 42 samples were obtained from patients with recurrent-acute
292 pouchitis and were used as a validation cohort in order to test our machine-learning classifier
293 predictions of pouchitis occurrence based on microbiome data. Patients with recurrent-acute pouchitis
294 suffer from up to 4 flares of pouchitis per year.

To explore the microbiomes of patients with a pouch in the context of primary IBD, we
295 analyzed shotgun metagenomes derived from fecal samples of patients with a pouch, UC, CD and
296 healthy subjects in terms of species composition and functional gene repertoires (Materials and
297 Methods). Metagenomes of patients with CD (n=88), UC (n=76) and of healthy subjects (n=56) were
298 obtained from data previously published in [18], which are part of the PRISM, LifeLines DEEP and
299 NLIBD cohorts (cross-sectional) (Supplementary Table 1C). To minimize potential biases, raw
300 metagenomic reads from all cohorts were processed in parallel through the same bioinformatic
301 pipeline, in line with recent recommendations for multi-cohort studies (²⁹Szamosi et al. 2020).

304 ***Microbial dysbiosis across disease phenotypes and its association with inflammation***

The microbial community composition among disease phenotypes and healthy subjects (beta-diversity,
305 analyzed by PCoA) was well separated according to profiles of species, genes and pathways (Fig. 1A-
306 C), with some degree of overlap, in particular between samples from UC and CD patients as was
307 observed previously [18]. Strikingly, we observed a significant stratification (Kruskal-Wallis $P < 0.01$)
308 of different disease phenotypes based on the first axis of microbiome variation, shifting away from the
309 healthy subjects, in the following order: UC, CD, normal pouch, and finally patients with pouchitis
310 (Fig. 1A-C). The latter was the most distant from the microbiomes of healthy controls, i.e. with the
311 highest level of dysbiosis. Interestingly, according to Shannon diversity (Fig. 1D), no significant
312 difference was observed between patients with CD (median Shannon 2.6) and UC (median Shannon
313 2.87) to patients with a normal pouch (median Shannon 2.73). In contrast, patients with pouchitis had
314 significantly lower diversity (median Shannon 2.31, Kruskal-Wallis $P < 0.001$) than all other
315 phenotypes. Patients with UC had significantly higher diversity than those with CD (Kruskal-Wallis P
316 = 0.0044) and only slightly lower diversity than that of healthy subjects (median Shannon 2.96,
317 Kruskal-Wallis $P = 0.004$), in agreement with previous reports [7].

The subject's clinical phenotype explained a modest part of the observed variation in microbial
320 composition (beta-diversity based on Bray-Curtis distance) in species, metabolic pathway and enzymes
321 composition (Supplementary Fig. 1; PERMANOVA, $R^2 = 12.1\%$, 13.2% , 10.4% respectively; $P <$
322 0.001), while patient age and gender (available only for the pouch cohort) explained only 0.39% to
323 0.71% and 0.42% to 0.52% , respectively. Antibiotic use (1-month or 6-months off-antibiotics)
324 accounted for only 0.45% to 0.62% of the variation. Fecal calprotectin, a biomarker for intestinal
325 inflammation, explained a low yet significant degree of microbial variation ($R^2 = 2.5\%$ to 4.1% , $P <$
326 0.001). Consistent with previous studies of patients with UC and CD [30, 13], inter-subject variation
327 explained the highest degree of microbiome variation (Supplementary Fig. 1D; PERMANOVA, $R^2 =$
328 46.6% to 48.7% , $P < 0.001$) among the longitudinal samples of patients with a pouch cohort. Finally, in
329 patients with a pouch cohort, pouch phenotype and disease activity contributed 4.2% to 4.8% and 1.4%
330 to 1.9% , respectively, to the variation in microbial species, pathways and enzymes (Supplementary Fig.
331 1D). These observations indicate that besides inter-subject differences, disease type and inflammation
332 severity are the strongest contributors to microbial variability and the resulting dysbiosis.

334 If dysbiosis is associated with intestinal inflammation, one would expect a correlation between
the microbiome variation described above and inflammation biomarkers. Indeed, we observed a
336 moderate and significant correlation between the fecal calprotectin level and the first axis of
microbiome variation for species, metabolic pathways and enzymes (Fig. 1E-G; Spearman $r = 0.44$,
0.39 and 0.375 respectively; $P < 0.001$). A weaker negative correlation was detected between
338 calprotectin and Shannon diversity (Fig. 1H; Spearman $r = -0.186$, $P = 4.01 \times 10^{-4}$). Patients with
pouchitis had the highest level of calprotectin, followed by patients with a normal pouch. Patients with
340 CD and UC had similar median calprotectin levels (Supplementary Fig. 2). Altogether these data
suggest that patients with a normal pouch already show signs of inflammation and dysbiosis that may
342 parallel those observed in CD, and that these are intensified in patients with pouchitis.

To rule out the possibility that the observed differences between the pouch to non-pouch
344 patients microbiomes are inflated due to center or country effects, we obtained 15 publicly available
pouch metagenomes [31] (an American cohort) and compared alpha and beta diversity across all the
346 analyzed metagenomes. Reassuringly, based on both microbiome species variation (Bray-Curtis) and
Shannon diversity (Supplementary Fig. 3), the pouch samples from [31] clustered within the range of
348 the pouches from our RMC pouch cohort.

350 ***Bacterial species associated with IBD***

We aimed to characterize the altered species composition in the four IBD groups compared to healthy
352 subjects, and also to compare patients with a pouch to primary IBD, using linear modeling of shotgun
metagenomic data. As expected, bacterial species composition showed extensive and significant
354 differences involving many taxa between healthy subjects and patients with UC, CD and with a pouch
(Fig. 2, Supplementary Table 3). We confirmed past observations of decreased abundance in beneficial
356 taxa such as *Faecalibacterium prausnitzii*, *Eubacterium rectale* and several *Roseburia* and *Bacteroides*
species and increased abundance of potential pathobionts such as *Escherichia coli*, *Pantoea* sp., and
358 several *Veillonella* and *Streptococcus* species in CD and in patients with a pouch [8, 10, 11, 12].
Patients with a pouch (in particular those with pouchitis) showed the strongest extremes in terms of the
360 levels of the above mentioned genera, further supporting the existence of a strong dysbiosis in
pouchitis.

In addition, we identified significant depletion of *Subdoligranulum* in all disease phenotypes
(Fig. 2), with the lowest abundance in patients with a pouch (normal pouch FDR $P = 0.025$, pouchitis
364 FDR $P = 0.01$). Species belonging to this genus, which is closely related to *Faecalibacterium*, have
been shown to produce the anti-inflammatory SCFA butyrate [32] and consequently may play a
366 protective role in the gut. Additionally, *Ruminococcus bromii*, a keystone species that is highly efficient
in the degradation of resistant starch, making its degradation products available for other beneficial
368 bacteria via cross-feeding [33], was highly depleted in all disease phenotypes, especially in patients
with a pouch (normal pouch FDR $P = 5.7 \times 10^{-7}$, pouchitis FDR $P = 7.5 \times 10^{-9}$). Interestingly, we found
370 that *Ruminococcus gnavus* and *Ruminococcus torques* were enriched in patients with a pouch (not
statistically significant), while *Akkermansia muciniphila* was depleted (Fig. 2, normal pouch FDR $P =$
372 0.12, pouchitis FDR $P = 0.15$). These three species have the potential to degrade human secretory
mucin, and a similar trend of increase in *R. gnavus* and *R. torques* coupled to a decrease in *A.*
374 *muciniphila* was previously reported in biopsies of UC and CD patients [34]. A higher proportion of *R.*
gnavus and *R. torques* in patients with a pouch may be an indication of excessive mucin degradation in
376 the pouch, which may contribute to increased intestinal inflammation [35]. Notably, a distinct clade of
R. gnavus strains was previously found to be enriched in CD and UC patients (marked by considerable

378 yet transient blooms) and harbored potential virulence-associated genes [36]. To critically examine the
hypothesis of increased mucin degradation potential in the pouch, we moved on to quantify the total
380 mucin-degrading bacterial enzymes in the gut microbiomes of these patients.

382 ***Mucin degradation and R. gnavus glycoside hydrolases***

We specifically analyzed glycoside hydrolase genes (GH) that are involved in the breakdown and
384 utilization of mucin-derived glycans and are encoded in the genomes of mucolytic bacteria. According
to these criteria, bacterial community mucin degradation potential in patients with a normal pouch was
386 similar to that of patients with CD (Kruskal-Wallis, $P = 0.08$) and to healthy subjects (Fig. 3A;
Kruskal-Wallis, $P = 0.374$). Patients with pouchitis had 12.3% lower community mucin degradation
388 potential than patients with a normal pouch (Kruskal-Wallis, $P = 3.4 \times 10^{-4}$), while patients with UC
had the lowest mucin degradation potential than the other phenotypes (Fig. 3A; Kruskal-Wallis, $P <$
390 0.01).

To better understand the specific role of *R. gnavus* in mucin degradation, we focused on its
392 enzymes that are considered specific for host mucin utilization: GH29 (Alpha-L-fucosidase), GH95
(glycoside hydrolase family 95) and GH33 (Exo-alpha-sialidase). The former two can cleave fucose
394 from host mucin glycans while the latter can cleave terminal sialic acid from sialylated mucins. It was
shown that the ability of *R. gnavus* to utilize host mucins is strain-dependent and is attributed to a
396 specific GH33 sialidase, and to GH29 and GH95 fucosidases [37] Crost et al. 2013]. Current HUMAnN2
enzyme annotation lacks *R. gnavus* as a contributor to Alpha-L-fucosidase (EC 3.2.1.51) and Exo-
398 alpha-sialidase (EC 3.2.1.18) enzymes (Fig. 3B,C). Thus we obtained sequences of GH29, GH95 and
GH33 from the representative genome of *Ruminococcus gnavus* ATCC-29149 JCM6515 and quantified
400 the abundance of these genes and the fraction of *R. gnavus* species that possess them in the
metagenomes by read-mapping. The fraction of *R. gnavus* strains encoding GH29 and GH95
402 fucosidases varied extensively across disease phenotypes (Fig. 3D,E), but was significantly higher in
patients with pouchitis with 39.6% and 25% (median) of the strains encoding these fucosidases,
404 respectively (Kruskal-Wallis, $P < 0.01$). No significant difference was observed between patients with a
normal pouch (11.3% and 10.1% median) and CD (18.3% and 13% median) for GH29 and GH95,
406 respectively. Less than 6% of *R. gnavus* in UC patients and in healthy subjects encoded these
fucosidases (Fig. 3D,E). Interestingly, GH33 sialidase was encoded by a significantly smaller
408 proportion of *R. gnavus* strains (Fig. 3F). Patients with a pouch had a similar fraction of *R. gnavus*-
encoded GH33 sialidase (normal pouch 2% and pouchitis 2.4% medians; Kruskal-Wallis, $P = 0.336$),
410 which was comparable to UC patients and healthy subjects (Kruskal-Wallis, $P > 0.05$). Patients with
CD had the highest abundance of *R. gnavus* strains encoding GH33 sialidase (Fig. 3F; 5.3% median;
412 Kruskal-Wallis, $P < 0.05$).

A study by [38] established that the pH level in patients with a normal pouch (5.4) was
414 significantly lower than in patients with pouchitis (6.5). Remarkably, this low pH in the normal pouch
substantially inhibited mucin (including fucose residues) degradation. This might explain why we
416 detected a markedly lower proportion of *R. gnavus* strains encoding fucosidases in patients with a
normal pouch. Altogether, our findings demonstrate that as a consequence of strong dysbiosis in
418 pouchitis, the overall bacterial community mucin degradation potential is lower, but there is a
significantly higher number of mucin-degrading *R. gnavus* strains that potentially might be pro-
420 inflammatory. Mucin degradation in a normal pouch is similar to that of CD both in terms of microbial
community- and *R. gnavus*-associated potential. These findings highlight the importance of mucin

422 degradation in intestinal inflammation, as well as the possible effect of disease phenotype and location
(whether small or large intestine).

424

Butyrate synthesis potential of the microbiome is deprived in pouchitis

426 Following our finding that patients with a pouch had greatly reduced abundances of beneficial species,
some of which are known SCFA producers, we aimed to directly quantify the genes encoding SCFA
428 synthesis enzymes. SCFA are the major metabolic products of anaerobic fermentation of non-digestible
polysaccharides by the human colonic microbiota [39, 40]. Here we focused on butyrate, as it is
430 considered to have the greatest benefit to the human host. Butyrate is the preferred energy source for
colonocytes, improves the gut barrier function, has immunomodulatory and anti-inflammatory
432 properties and reduces oxidative stress in the colon [39]. Butyrate-producing species are found among
many butyrate non-producing species in two dominant families of Firmicutes, *Ruminococcaceae* and
434 *Lachnospiraceae* [40]. Four main pathways are known for butyrate production: the acetyl-CoA,
glutarate, 4-aminobutyrate, and lysine pathways. Acetyl-CoA is the dominant pathway for butyrate
436 synthesis and is present in the majority of butyrate producers and *but* is the most prevalent terminal
gene [41].

438 We quantified and modeled the terminal genes of the four known butyrate production pathways,
namely *but*, *buk*, *ato* and *4hbt* (see Materials and Methods) in the metagenomes using an extensive and
440 rigorously-curated database for butyrate synthesis genes [24]. Overall, patients with CD, normal pouch
and pouchitis had significantly lower levels of butyrate synthesis pathways compared to healthy
442 subjects (Fig. 4A-D; $P < 0.05$). Specifically, according to the *but* gene (Fig. 4A, E), the lowest
abundance of these genes was in patients with pouchitis (median RPKM 12), followed by significantly
444 higher abundance in patients with a normal pouch (median RPKM 78; Kruskal-Wallis, $P = 3.5 \times 10^{-6}$).
No significant difference in butyrate synthesis genes between CD (median RPKM 126) and UC
446 (median RPKM 136) was observed, but both were significantly lower than in healthy subjects (median
RPKM 175; Kruskal-Wallis, $P = 3 \times 10^{-5}$, $P = 0.002$, respectively) and higher than in pouch
448 phenotypes. Analysis of the *buk* homologs (Fig. 4B, F) revealed no significant difference in abundance
between patients with CD (median RPKM 6.6) and with normal pouch (median RPKM 8.4) or with
450 pouchitis (median RPKM 4.75), but patients with pouchitis had a lower abundance of *buk* than with
normal pouch (Kruskal-Wallis, $P = 0.025$). Patients with UC and healthy subjects had the highest gene
452 abundance (Kruskal-Wallis, $P < 0.01$). The lysine (*ato*) and 4-aminobutyrate (*4hbt*) pathways were
negatively associated with patients with a pouch (Fig. 4C, D), and were less abundant in general in all
454 groups, presenting similar trends (Fig. 4G, H). Patients with a pouch had very low levels of both *ato*
and *4hbt* genes (were missing altogether in many samples) suggesting that the 4-aminobutyrate and
456 lysine pathways for butyrate synthesis are exceptionally low in these patients.

458 The taxonomic affiliation of butyrate-producing bacteria based on the similarity of the
identified *but* and *buk* genes to known butyrate producers revealed a dominance of commensal
Firmicutes such as *F. prausnitzii* and several species of *Roseburia* and *Eubacterium* (Supplementary
460 Fig. 4). Surprisingly, healthy subjects had a somewhat low relative abundance of some of these
butyrate producers compared to disease phenotypes, which might be a result of the higher bacterial
462 diversity in healthy, and consequently a lower “reliance” on a few species for butyrate production. *F.*
prausnitzii, *E. hali*, and *Subdoligranulum variabile* had comparable relative abundances in patients
464 with normal pouch, UC and healthy, while patients with pouchitis and CD had low levels of these taxa.
For a complete list of all the identified butyrate producers, see Supplementary Table 4. Interestingly,

466 *ato*-encoding *Alistipes putredinis* and *Odoribacter splanchnicus* (Bacteroidetes), were abundant only in
non-pouch patients. Conversely, *Cetobacterium somerae* (Fusobacteria) encoding *ato* was highly
468 abundant in seven samples from patients with a pouch and in only a single sample from a CD patient.
Notably, a significant negative correlation was observed between the abundance of butyrate synthesis
470 genes and fecal calprotectin (Supplementary Fig. 5). This was most pronounced for the *but* gene
(Spearman $r = -0.322$, $P = 4.34 \times 10^{-10}$). This suggests that either a reduction in butyrate producers
472 predisposes to intestinal inflammation or that butyrate-producing bacteria are more sensitive to
intestinal inflammation.

474 As butyrate production may be affected by patients' dietary habits, especially dietary fiber
consumption, we correlated the average daily intake of dietary fiber derived from different food sources
476 with butyrate synthesis genes in a subset of samples ($n=52$) that had dietary information (FFQs
obtained at the time of fecal samples collection) - Table 1. The abundance of *but* and *buk* genes were
478 positively correlated with total dietary fiber intake (Spearman $r = 0.366$, $P = 0.0076$), and specifically
with intake of fiber from fruit (Spearman $r = 0.293$, $P = 0.035$), vegetables (Spearman $r = 0.275$, $P =$
480 0.048) and potatoes (Spearman $r = 0.46$, $P = 6 \times 10^{-4}$). Higher fruit consumption had been previously
associated with increased abundance of known butyrate-producing species, and lower recurrence of
482 pouchitis [42]. Nutritional intervention for patients with a pouch, such as the Mediterranean diet was
previously associated with decreased inflammatory markers and later onset of pouchitis and is
484 characterized by a high intake of dietary fibers [43]. Our results, therefore highlight diet as an
important factor that may affect butyrate synthesis and provide further support for dietary intervention
486 as a plausible approach to modulate the microbiota and increase the low butyrate levels in the pouch.

Previous studies examining butyrate-producing bacteria, their gene content or metabolites in
488 IBD reported various results. A study of [44] reported no difference in butyrate concentrations in fecal
samples between healthy subjects and UC patients. On the other hand, fecal butyrate concentrations
490 were decreased in both CD and (to a lesser degree) UC patients in earlier studies [45, 46]. According to
the quantification of *but* gene content, reduced butyrate synthesis was identified in patients with active
492 and inactive CD but only in patients with active UC [47]. In patients with a pouch, data about butyrate
production is scarce and butyrate synthesis genes had not been previously analyzed. It was suggested
494 that bacterial dysbiosis in pouchitis causes SCFA deprivation [6], which might be related to the
pathogenesis of pouchitis. Fecal levels of SCFA in patients with pouchitis were substantially lower
496 compared to patients with a normal pouch [48, 49], which may contribute to the higher pH observed in
pouchitis [38]. These past observations of butyrate and pH levels in the pouch are in line with our
498 metagenomics-based findings and suggest that a shortage of butyrate (and its producers) is an important
contributor to the pathogenesis of pouchitis. This may be clinically relevant as SCFA enemas were
500 successfully assessed for the treatment of diversion colitis [50] and for UC [51]. Their effect in
pouchitis was rarely assessed in small uncontrolled trials and case studies [52]. Our findings provide a
502 mechanistic rationale for a reassessment of this therapy in pouchitis.

504 **Secondary bile acids production potential is low in pouchitis**

Secondary bile acids deoxycholic acid (DCA) and lithocholic acid (LCA) are formed in the colon from
506 primary bile acids metabolism by the microbiota via a multi-step 7α -dehydroxylation reaction.
Secondary bile acids (DCA and LCA) have extensive effects on host metabolism and play both
508 negative and positive roles in health and disease [53]. The level of DCA in bile is thought to be
controlled by two major factors: levels and activities of bile acid 7α -dehydroxylating gut microbes and

510 colonic transit time [53]. In IBD, impaired fecal bile acid metabolism was observed, with an increase in
511 primary bile acids and a decrease in secondary bile acids (particularly during flares). *In-vitro* and *in-*
512 *vivo* experimental models confirmed that DCA and LCA may exert anti-inflammatory effects [54, 55].
513 Enzymes involved in 7 α -dehydroxylation are encoded by bile acid inducible (*bai*) gene clusters present
514 in bacterial genomes from *Ruminococcaceae* and to a lesser extent from *Lachnospiraceae* and
515 *Peptostreptococcaceae* [56]. The *bai* genes cluster was found to be encoded and expressed in the gut
516 microbiomes of most individuals, however only in a small fraction (<1%) of total intestinal bacteria
[25].

517 We quantified and modeled the *bai* genes cluster (see Materials and Methods) in the
518 metagenomes of IBD and healthy subjects using an extensive and rigorously curated database for
519 secondary bile acids formation genes [25]. Patients with CD, normal pouch, and pouchitis were
520 significantly associated with a decreased secondary bile acid formation potential (Fig. 5A; $P < 0.05$). In
521 line with the highest dysbiosis in patients with pouchitis, the *bai* gene cluster abundance was lowest in
522 this group (median RPKM 21.3), but was higher in patients with a normal pouch (Fig. 5B; median
523 RPKM 44.6; Kruskal-Wallis, $P = 0.002$). UC and CD patients had comparable levels of *bai* genes
524 abundance (median RPKM 72.6 and 71, respectively; Kruskal-Wallis, $P = 0.29$), and both were
525 significantly higher than in patients with pouch (Kruskal-Wallis, $P < 0.001$). Healthy individuals had
526 the highest abundance of *bai* genes of all phenotypes (Fig. 5B; median RPKM 101; Kruskal-Wallis, $P <$
527 0.01).

528 Only several dominant strains in the analyzed metagenomes were identified to encode the *bai*
529 gene clusters (or parts of). They belonged to three families of Firmicutes: *Lachnospiraceae*
530 (*Clostridium scindens*), *Peptostreptococcaceae* (*Clostridium sordellii* and *Proteocatella sphenisci*) and
531 *Ruminococcaceae* (uncultured strains of Firmicutes bacterium CAG:103, Clostridiales bacterium
532 UBA4701 and UBA1701). For a complete list of the identified secondary bile acid producers, see
533 Supplementary Table 4. Importantly, the abundance of *bai* gene cluster was significantly negatively
534 correlated with fecal calprotectin (Supplementary Fig. 6; Spearman $r = -0.312$, $P = 1.64 \times 10^{-9}$),
535 implying that DCA and LCA producing bacteria are associated with lower levels of intestinal
536 inflammation.

537 A reduction in secondary bile acids genes in patients with CD or UC [25, 57] as well as a
538 reduction in DCA and LCA metabolites in highly-dysbiotic patients with UC and CD, was previously
539 described [13], supporting our current study. The key species encoding *bai* clusters in our
540 metagenomes are concordant with those identified in metagenomes of a healthy population [56].
541 Importantly, one of the prevalent secondary bile acids producers we detected, *C. scindens*, was
542 associated with enhanced resistance to *C. difficile* infection in a secondary bile acid dependent manner
543 [58]. The reduction of secondary bile acid-producing bacteria in IBD and particularly in pouchitis
544 might leave these patients more exposed to pathogens or potential pathobionts. Interestingly, patients
545 with an ileal pouch were previously shown to have markedly lower levels of biliary and fecal DCA and
546 LCA levels (compared to healthy controls), while fecal primary bile acids excretion was significantly
547 higher, indicating attenuated bacterial conversion [59]. These measurements complement our
548 metagenomic findings and support our hypothesis that a reduction in 7 α -dehydroxylation bacterial
549 enzymes leads to a pouch microbiome with lower potential for producing secondary bile acids.

552 ***Enzymes related to protection against oxidative stress are highly prevalent in patients with a pouch***

553 Previous studies suggested higher oxidative stress in the inflamed gut of patients with UC and CD [60,
554 9, 36]. Here we aimed to characterize and quantify genes that encode enzymes involved in oxidative

stress response (oxygen-detoxifying enzymes) as a proxy for the levels of oxygen-tolerance of
556 microbes in the metagenomes of patients with IBD. We used the enzyme profiles annotated with
HUMAnN2 and extracted such oxygen-detoxifying enzymes.

558 We detected a significant increase in the abundance of genes encoding two enzymes responsible
for the synthesis of glutathione, an important antioxidant [61], namely glutamate-cysteine ligase (EC
560 6.3.2.2) and glutathione synthase (EC 6.3.2.3), in patients with CD and more so in patients with a
pouch (Fig 6A, B, Fig. 7A, Supplementary Table 5), again supporting similarities between these
562 conditions. Furthermore, the gene encoding for glutathione-disulfide reductase (EC 1.8.1.7), which
serves to maintain glutathione in the reduced form, was highly enriched in patients with a pouch (Fig
564 6C, Fig. 7A, Supplementary Table 5) (normal pouch FDR $P = 9.8 \times 10^{-11}$, pouchitis FDR $P = 1.2 \times 10^{-13}$).
A trend of higher abundance of genes encoding for superoxide dismutase (EC 1.15.1.1; normal
566 pouch FDR $P = 0.65$, pouchitis FDR $P = 0.23$, not statistically significant) and peroxiredoxin (EC
1.11.1.15; normal pouch FDR $P = 0.15$, pouchitis FDR $P = 0.15$) was detected in patients with a pouch,
568 further supporting the notion of a pouch environment with a high oxidative stress (Fig 6D, E, Fig. 7A,
Supplementary Table 5). Both of these enzyme families are known to play a central role in oxidative
570 stress response [62, 63]. Finally, genes encoding methionine sulfoxide reductase (EC 1.8.4.11), an
enzyme that reduces the oxidized form of methionine back to the active amino acid thereby reactivating
572 damaged peptides [64], were elevated in patients with pouchitis (FDR $P = 0.22$, not statistically
significant; Fig 6F, Fig. 7A, Supplementary Table 5). The combined contribution of these six oxidative
574 stress response enzymes (“total oxidative stress response”) was the highest in patients with pouchitis
(median RPKM 385; Kruskal-Wallis, $P < 0.05$), followed by patients with a normal pouch (median
576 RPKM 282; Kruskal-Wallis, $P < 0.05$), and was significantly lower in the other phenotypes (Fig. 7B).

A clear difference was observed between the highly contributing species to these anti-oxidative
578 stress enzymes in pouch compared to non-pouch phenotypes. In the former, the vast majority consisted
of facultative anaerobes such as *E. coli* and to a lesser degree *Klebsiella* and few species of
580 *Streptococcus* and *Lactobacillus*. In the latter, *E. coli* contribution was less pronounced and replaced by
obligate anaerobes such as *Bacteroides* species, several Clostridiales species, *A. muciniphila*,
582 *Bifidobacterium longum* and *Prevotella copri* (Fig 6). A similar trend of increased facultative
anaerobes abundance was previously observed in patients with CD or UC compared to healthy
584 individuals [36]. Our results suggest that microbes that are more oxygen-tolerant and encode more
oxygen-detoxifying enzymes have a fitness advantage and become more abundant in the high oxidative
586 environment of the pouch.

588 **Classification models to distinguish between patients with a normal pouch and pouchitis based on species and functional biomarkers**

590 We observed multiple differences in species and functional genes between patients with a normal
pouch and those with pouchitis, yet no bacterial feature on its own was highly discriminative. We,
592 therefore, attempted to use bacterial composition, metabolic pathways and enzymes profiles in order to
build classifiers that will distinguish between these pouch phenotypes in the discovery cohort. In
594 addition, we used the classifier built on our discovery cohort to classify samples with recurrent-acute
pouchitis from the validation cohort in order to test if the model is able to correctly predict whether
596 these patients will become normal pouch (disease improvement) or pouchitis (disease aggravation) in
follow-up clinic visits. We used a machine learning algorithm of gradient boosting trees (GBT, see

598 Materials and Methods) to train the classifier and evaluated its performance using five-fold cross-validation.

600 The GBT classifier based on the full set of species profile (230 features) achieved a mean area under the curve (AUC) of 0.787 ± 0.067 (Fig. 8A) for correctly classifying pouch samples into normal pouch or pouchitis. To improve the model's predictive power, we used the feature importance scores that the algorithm assigns to each feature used during training, therefore features with the highest scores are the most informative for classification (Materials and Methods). A GBT classifier trained on the 40-top scoring features (species) showed improved performance with AUC of 0.818 ± 0.058 (Fig. 602 8A). Slightly improved outcomes were noticed when fecal calprotectin was incorporated into the model as a predictor (AUC= 0.835 ± 0.055). Next, we built GBT models with metabolic pathways (MetaCyc) 604 and microbial enzymes (ECs) as features. The pathway-based GBT model with a full set of 395 features achieved AUC of 0.76 ± 0.065 (Fig. 8B), while a model with the 60-top scoring features 606 achieved AUC of 0.834 ± 0.056 , a similar performance to the species based classifier. Importantly, GBT models trained on bacterial enzymes achieved better classification scores than species- or 608 metabolic pathways-based models, despite having a larger number of features (1646) (Fig. 8C). The model with a full set of enzymes had an AUC of 0.802 ± 0.064 , whereas, in a model with a reduced set of topmost 100 features, the AUC increased to 0.91 ± 0.046 (Fig. 8C). Fecal calprotectin did not 614 notably improve the pathways and enzymes models. Furthermore, as the sole predictive feature, fecal calprotectin achieved a poor AUC of 0.625 ± 0.077 (Fig. 8D) in distinguishing normal pouch from 616 pouchitis patients.

618 By analyzing the best predicting microbial features, we can gain new insights and identify potential biomarkers to disease pathogenesis. Reassuringly, among the highest-scoring features 620 (species, pathways and enzymes) our models selected to best distinguish patients with pouchitis from a normal pouch, appeared many of the features mentioned above that differed significantly between these 622 phenotypes and with potential clinical relevance to pouchitis pathogenesis (Supplementary Fig. 7, Supplementary Table 6).

624 Finally, we used the best species model (with 40 top scoring features) trained on the discovery cohort (n=208 samples), to test the model's ability to correctly classify samples with recurrent-acute 626 pouchitis phenotype from the validation cohort (n=42 samples) according to their future phenotype. We defined the true label of these samples according to the last recorded phenotype during clinic visit 628 (future clinical observation compared to the current sample), when these patients' phenotype changed either to a normal pouch or to pouchitis. Our species model (with or without calprotectin as an 630 additional predictor) achieved an AUC of 0.778 (Supplementary Fig. 8A), but other performance metrics were better when including calprotectin: accuracy 76.2%, sensitivity: 88.9% and specificity: 632 53.3%. Notably, the sensitivity was high, the model correctly classified 24/27 recurrent-acute cases that later changed to pouchitis, however, the specificity was very low and only 8/15 that changed to normal 634 pouch were classified correctly (Supplementary Fig. 8B). This implies that our classifier has a tendency to classify patients with recurrent-acute pouchitis more often into "pouchitis" rather than "normal 636 pouch" and that recurrent-acute patients have a microbial profile more similar to patients with pouchitis.

638 In summary, given the complexity of the pouch microbiome, the challenge in classifying patients into normal pouch or pouchitis based on metagenomic biomarkers is not surprising. 640 Nonetheless, functional genes had better classifying power than species composition, as the former incorporate enzymatic functions that are sometimes strain-specific (as in the *R. gnavus* example above) 642 as well as those functions that can be encoded by many diverse species. It is possible to "predict" which patients with recurrent-acute pouchitis phenotype will develop into pouchitis or improve into a normal

644 pouch, but this requires further validation in a larger cohort of such patients. Importantly, these
analyses support our notion that not only does the pouch represent an unstable milieu, this milieu tends
646 to be pro-inflammatory in nature.

648 **Conclusions**

In this study, we explored bacterial functional dysbiosis in a well-phenotyped cohort of patients with a
650 pouch. We identified several metabolic pathways and enzymes that were altered in patients with a
pouch compared to patients with CD or UC and healthy controls. Most notably, the functional dysbiosis
652 was more severe in patients with pouchitis, characterized by a shortage of genes for synthesis of
butyrate and secondary bile acids. Moreover, patients with pouchitis harbored more facultative
654 anaerobic bacteria encoding anti-oxidative stress enzymes, suggesting high oxidative stress during
pouch inflammation. It appears that there is no excessive bacterial mucus utilization and degradation in
656 the pouch, but rather a change in the mucolytic bacterial community composition, highlighted by an
increased fraction of *R. gnavus* strains encoding fucosidases. We propose that the normal pouch and
658 more so pouchitis are already dysbiotic (function- and species-wise) and based on multiple features,
pouch phenotypes are more similar to CD. Our machine learning models emphasize the importance of
660 integrating microbial-based biomarkers into clinical diagnostic tools. Our findings also delineate
microbial and functional factors that underlie the pathogenesis of pouchitis and may suggest pathways
662 such as butyrate that could be targeted for intervention in combination with dietary changes such as
higher intake of fibers, to attenuate small intestinal inflammation, such as in pouchitis and CD.

664

List of abbreviations

666 IBD: inflammatory bowel diseases

CD: Crohn's disease

668 UC: ulcerative colitis

SCFA: short-chain fatty acid

670 CLDP: Crohn's like disease of the pouch

EC: Enzyme Commission number

672 GH: glycoside hydrolases

GBT: gradient boosting trees

674 AUC: under the curve

DCA: deoxycholic acid

676 LCA: lithocholic acid

RPKM: reads per kilobase per million mapped reads

678 cpm: copies per million

680 **Declarations**

Ethics approval and consent to participate

682 The study was approved by the local institutional review board (0298–17) and the National Institutes of Health (NCT01266538). All patients signed informed consent before inclusion to the study.

684

Consent for publication

686 Not applicable.

688 **Competing interests**

Iris Dotan: Consultation/advisory boards for Pfizer, Janssen, Abbvie, Takeda, Roche/Genentech, Celltrion, Celgene, Medtronic/Given Imaging, Rafa Laboratories, Neopharm, Sublimity, Arena, Gilead. Speaking/teaching: Pfizer, Janssen, Abbvie, Takeda, Roche/Genentech, Celltrion, Celgene, Falk Pharma, Ferring. Grant support: Pfizer, Altman Research. The remaining authors declare no competing interests

694

Funding

696 This work was supported by a generous grant from the Leona M. and Harry B. Helmsley Charitable Trust. V.D. was partially supported by a fellowship from the Edmond J. Safra Center for Bioinformatics at Tel-Aviv University. U.G. was also supported by the Israeli Ministry of Science and Technology.

700

Authors' contributions

702 V.D., U.G. and I.D. conceived and designed the study; V.D. developed the bioinformatic analysis and machine learning pipelines and analyzed the metagenomic data; L.R. analyzed the metagenomic data; K.R., L.G., K.Y., K.Z. and I.D. collected, analyzed and provided the clinical data; N.W. and I.D. enrolled and examined the patients; L.G. provided and analyzed the dietary information. V.D., L.R., U.G. and I.D. wrote the paper. All authors read, discussed, and approved the final manuscript.

708 **Acknowledgments**

The authors wish to thank the members of the RMC IBD Center and the Comprehensive Pouch Clinic for their help and stimulating discussion of the project. The authors wish to thank Stefan Green of the University of Illinois at Chicago, for his continued expert help in the metagenomic sequencing.

712

714 **References**

1. Lees, C. W., Barrett, J. C., Parkes, M. & Satsangi, J. New IBD genetics: common pathways with other diseases. *Gut* **60**, 1739–1753 (2011).

716

- 718 2. Ananthakrishnan, A. N. *et al.* Environmental triggers in IBD: a review of progress and evidence. *Nature Reviews Gastroenterology & Hepatology* **15**, 39–49 (2017).
- 720 3. Sartor, R. B. & Wu, G. D. Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches. *Gastroenterology* **152**, 327–339.e4 (2017).
- 722 4. Shen, B., Fazio, V. W., Remzi, F. H. & Lashner, B. A. Clinical Approach to Diseases of Ileal Pouch-Anal Anastomosis. *The American Journal of Gastroenterology* **100**, 2796–2807 (2005).
- 724 5. Tulchinsky, H. *et al.* Comprehensive pouch clinic concept for follow-up of patients after ileal pouch anal anastomosis: Report of 3 years' experience in a tertiary referral center: *Inflammatory Bowel Diseases* **14**, 1125–1132 (2008).
- 726 6. Schieffer, K. M., Williams, E. D., Yochum, G. S. & Koltun, W. A. Review article: the pathogenesis of pouchitis. *Alimentary Pharmacology & Therapeutics* **44**, 817–835 (2016).
- 728 7. Willing, B. P. *et al.* A Pyrosequencing Study in Twins Shows That Gastrointestinal Microbial Profiles Vary With Inflammatory Bowel Disease Phenotypes. *Gastroenterology* **139**, 1844–1854.e1 (2010).
- 730 8. Sokol, H. *et al.* Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. *Proceedings of the National Academy of Sciences* **105**, 16731–16736 (2008).
- 732 9. Morgan, X. C. *et al.* Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. *Genome biology* **13**, R79 (2012).
- 734 10. Gevers, D. *et al.* The Treatment-Naive Microbiome in New-Onset Crohn's Disease. *Cell Host & Microbe* **15**, 382–392 (2014).
- 736 11. Reshef, L. *et al.* Pouch Inflammation Is Associated With a Decrease in Specific Bacterial Taxa. *Gastroenterology* **149**, 718–727 (2015).
- 738 12. Dubinsky, V. *et al.* Predominantly Antibiotic-resistant Intestinal Microbiome Persists in Patients With Pouchitis Who Respond to Antibiotic Therapy. *Gastroenterology* **158**, 610–624.e13 (2020).
- 740 13. IBDMDB Investigators *et al.* Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. *Nature* **569**, 655–662 (2019).
- 742 14. Ben-Shachar, S. *et al.* Gene Expression Profiles of Ileal Inflammatory Bowel Disease Correlate with Disease Phenotype and Advance Understanding of Its Immunopathogenesis: *Inflammatory Bowel Diseases* **19**, 2509–2521 (2013).
- 744 15. Ben-Shachar, S. *et al.* MicroRNAs Expression in the Ileal Pouch of Patients with Ulcerative Colitis Is Robustly Up-Regulated and Correlates with Disease Phenotypes. *PLOS ONE* **11**, e0159956 (2016).
- 746 16. Goren, I., Yahav, L., Tulchinsky, H. & Dotan, I. Serology of Patients with Ulcerative Colitis After Pouch Surgery Is More Comparable with that of Patients with Crohn's Disease: *Inflammatory Bowel Diseases* **1** (2015) doi:10.1097/MIB.0000000000000487.
- 748 17. Sandborn, W. J., Tremaine, W. J., Batts, K. P., Pemberton, J. H. & Phillips, S. F. Pouchitis After Ileal Pouch-Anal Anastomosis: A Pouchitis Disease Activity Index. *Mayo Clinic Proceedings* **69**, 409–415 (1994).
- 750 18. Franzosa, E. A. *et al.* Gut microbiome structure and metabolic activity in inflammatory bowel disease. *Nature Microbiology* (2018) doi:10.1038/s41564-018-0306-4.
- 752 19. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* **30**, 2114–2120 (2014).
- 754 20. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nature Methods* **9**, 357–359 (2012).
- 756 21. Truong, D. T. *et al.* MetaPhlan2 for enhanced metagenomic taxonomic profiling. *Nature methods* **12**, 902 (2015).
- 760 22. Franzosa, E. A. *et al.* Species-level functional profiling of metagenomes and metatranscriptomes. *Nature Methods* **15**, 962–968 (2018).
- 762 23. Buchfink, B., Xie, C. & Huson, D. H. Fast and sensitive protein alignment using DIAMOND. *Nature Methods* **12**, 59–60 (2015).
- 764 24. Vital, M., Karch, A. & Pieper, D. H. Colonic Butyrate-Producing Communities in Humans: an Overview Using Omics Data. *mSystems* **2**, (2017).
- 766 25. Rath, S., Rud, T., Karch, A., Pieper, D. H. & Vital, M. Pathogenic functions of host microbiota. *Microbiome* **6**, (2018).
- 768 26. Tailford, L. E., Crost, E. H., Kavanaugh, D. & Juge, N. Mucin glycan foraging in the human gut microbiome. *Frontiers in Genetics* **6**, (2015).
- 770 27. Lombard, V., Golaconda Ramulu, H., Drula, E., Coutinho, P. M. & Henrissat, B. The carbohydrate-active enzymes database (CAZy) in 2013. *Nucleic Acids Research* **42**, D490–D495 (2014).
- 772 28. Chen, T. & Guestrin, C. XGBoost: A Scalable Tree Boosting System. in *Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining - KDD '16* 785–794 (ACM
- 774

- Press, 2016). doi:10.1145/2939672.2939785.
- 776 29. Szamosi, J. C. *et al.* Assessment of Inter-Laboratory Variation in the Characterization and Analysis of the
Mucosal Microbiota in Crohn's Disease and Ulcerative Colitis. *Frontiers in Microbiology* **11**, (2020).
- 778 30. Schirmer, M. *et al.* Dynamics of metatranscription in the inflammatory bowel disease gut microbiome.
Nature Microbiology **3**, 337–346 (2018).
- 780 31. Sinha, S. R. *et al.* Dysbiosis-Induced Secondary Bile Acid Deficiency Promotes Intestinal Inflammation. *Cell*
Host & Microbe **27**, 659–670.e5 (2020).
- 782 32. Holmstrøm, K., Collins, M. D., Møller, T., Falsen, E. & Lawson, P. A. Subdoligranulum variabile gen. nov.,
sp. nov. from human feces. *Anaerobe* **10**, 197–203 (2004).
- 784 33. Ze, X., Duncan, S. H., Louis, P. & Flint, H. J. Ruminococcus bromii is a keystone species for the degradation
of resistant starch in the human colon. *The ISME Journal* **6**, 1535–1543 (2012).
- 786 34. Png, C. W. *et al.* Mucolytic Bacteria With Increased Prevalence in IBD Mucosa Augment In Vitro
Utilization of Mucin by Other Bacteria. *The American Journal of Gastroenterology* **105**, 2420–2428 (2010).
- 788 35. Ganesh, B. P., Klopfleisch, R., Loh, G. & Blaut, M. Commensal Akkermansia muciniphila Exacerbates Gut
Inflammation in Salmonella Typhimurium-Infected Gnotobiotic Mice. *PLoS ONE* **8**, e74963 (2013).
- 790 36. Hall, A. B. *et al.* A novel Ruminococcus gnavus clade enriched in inflammatory bowel disease patients.
Genome Medicine **9**, (2017).
- 792 37. Crost, E. H. *et al.* Utilisation of Mucin Glycans by the Human Gut Symbiont Ruminococcus gnavus Is
Strain-Dependent. *PLoS ONE* **8**, e76341 (2013).
- 794 38. Ruseler-van Embden, J. G., Schouten, W. R. & van Lieshout, L. M. Pouchitis: result of microbial imbalance?
Gut **35**, 658–664 (1994).
- 796 39. Rivière, A., Selak, M., Lantin, D., Leroy, F. & De Vuyst, L. Bifidobacteria and Butyrate-Producing Colon
Bacteria: Importance and Strategies for Their Stimulation in the Human Gut. *Frontiers in Microbiology* **7**,
798 (2016).
40. Louis, P. & Flint, H. J. Formation of propionate and butyrate by the human colonic microbiota: Propionate
and butyrate producing gut microbes. *Environmental Microbiology* **19**, 29–41 (2017).
- 800 41. Vital, M., Howe, A. C. & Tiedje, J. M. Revealing the Bacterial Butyrate Synthesis Pathways by Analyzing
802 (Meta)genomic Data. *mBio* **5**, (2014).
42. Godny, L. *et al.* Fruit Consumption is Associated with Alterations in Microbial Composition and Lower
804 Rates of Pouchitis. *Journal of Crohn's and Colitis* **13**, 1265–1272 (2019).
43. Godny, L. *et al.* Adherence to the Mediterranean diet is associated with decreased fecal calprotectin in
806 patients with ulcerative colitis after pouch surgery. *European Journal of Nutrition* (2019)
doi:10.1007/s00394-019-02158-3.
- 808 44. Machiels, K. *et al.* A decrease of the butyrate-producing species *Roseburia hominis* and *Faecalibacterium*
prausnitzii defines dysbiosis in patients with ulcerative colitis. *Gut* **63**, 1275–1283 (2014).
- 810 45. Marchesi, J. R. *et al.* Rapid and Noninvasive Metabonomic Characterization of Inflammatory Bowel
Disease. *Journal of Proteome Research* **6**, 546–551 (2007).
- 812 46. Takaishi, H. *et al.* Imbalance in intestinal microflora constitution could be involved in the pathogenesis of
inflammatory bowel disease. *International Journal of Medical Microbiology* **298**, 463–472 (2008).
- 814 47. Laserna-Mendieta, E. J. *et al.* Determinants of Reduced Genetic Capacity for Butyrate Synthesis by the Gut
Microbiome in Crohn's Disease and Ulcerative Colitis. *Journal of Crohn's and Colitis* **12**, 204–216 (2018).
- 816 48. Clausen, M. R., Tvede, M. & Mortensen, P. B. Short-chain fatty acids in pouch contents from patients with
and without pouchitis after ileal pouch-anal anastomosis. *Gastroenterology* **103**, 1144–1153 (1992).
- 818 49. Sagar, P. M. *et al.* Acute pouchitis and deficiencies of fuel: *Diseases of the Colon & Rectum* **38**, 488–493
(1995).
- 820 50. Harig, J. M., Soergel, K. H., Komorowski, R. A. & Wood, C. M. Treatment of Diversion Colitis with Short-
Chain-Fatty Acid Irrigation. *New England Journal of Medicine* **320**, 23–28 (1989).
- 822 51. Scheppach, W. *et al.* Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis.
Gastroenterology **103**, 51–56 (1992).
- 824 52. Wischmeyer, P., Pemberton, J. H. & Phillips, S. F. Chronic Pouchitis After Ileal Pouch-Anal Anastomosis:
Responses to Butyrate and Glutamine Suppositories in a Pilot Study. *Mayo Clinic Proceedings* **68**, 978–981
826 (1993).
53. Ridlon, J. M., Harris, S. C., Bhowmik, S., Kang, D.-J. & Hylemon, P. B. Consequences of bile salt
828 biotransformations by intestinal bacteria. *Gut Microbes* **7**, 22–39 (2016).
54. Duboc, H. *et al.* Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel
830 diseases. *Gut* **62**, 531–539 (2013).
55. Ward, J. B. J. *et al.* Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon.
832 *American Journal of Physiology-Gastrointestinal and Liver Physiology* **312**, G550–G558 (2017).

- 834 56. Vital, M., Rud, T., Rath, S., Pieper, D. H. & Schlüter, D. Diversity of Bacteria Exhibiting Bile Acid-
inducible 7 α -dehydroxylation Genes in the Human Gut. *Computational and Structural Biotechnology Journal*
17, 1016–1019 (2019).
- 836 57. Das, P., Marcišauskas, S., Ji, B. & Nielsen, J. Metagenomic analysis of bile salt biotransformation in the
human gut microbiome. *BMC Genomics* 20, (2019).
- 838 58. Buffie, C. G. *et al.* Precision microbiome reconstitution restores bile acid mediated resistance to *Clostridium*
difficile. *Nature* 517, 205–208 (2015).
- 840 59. Hakala, K., Vuoristo, M., Luukkonen, P., Jarvinen, H. J. & Miettinen, T. A. Impaired absorption of
cholesterol and bile acids in patients with an ileoanal anastomosis. *Gut* 41, 771–777 (1997).
- 842 60. Keshavarzian, A. Increases in free radicals and cytoskeletal protein oxidation and nitration in the colon of
patients with inflammatory bowel disease. *Gut* 52, 720–728 (2003).
- 844 61. Forman, H. J., Zhang, H. & Rinna, A. Glutathione: Overview of its protective roles, measurement, and
biosynthesis. *Molecular Aspects of Medicine* 30, 1–12 (2009).
- 846 62. Miller, A.-F. Superoxide dismutases: Ancient enzymes and new insights. *FEBS Letters* 586, 585–595 (2012).
- 848 63. Dubbs, J. M. & Mongkolsuk, S. Peroxiredoxins in Bacterial Antioxidant Defense. in *Peroxiredoxin Systems*
(eds. Flohé, L. & Harris, J. R.) vol. 44 143–193 (Springer Netherlands, 2007).
- 850 64. Weissbach, H. *et al.* Peptide Methionine Sulfoxide Reductase: Structure, Mechanism of Action, and
Biological Function. *Archives of Biochemistry and Biophysics* 397, 172–178 (2002).

852

Figures and Tables

854

856 **Table 1.** Spearman correlation between dietary fiber intake and the abundance of butyrate genes (*but* +
buk) in patients with a pouch samples [n=52].

Fiber sources [g/day]	<i>rho</i>	<i>P</i>
Fiber – Total	0.366	0.0076
Fiber – Fruits	0.293	0.0346
Fiber – Vegetables	0.275	0.0479
Fiber – Potatoes	0.46	6 x 10 ⁻⁴
Fiber – Grains	-0.08	0.5729
Fibers – Legumes and Nuts	0.1	0.4847

858





Fig. 1 Microbial community stratification among disease phenotypes and healthy subjects. The microbiome variation according to the first axes of principal coordinates analysis (PCoA) of (A) species, (B) metabolic pathways and (C) enzymes profiles, based on Bray-Curtis dissimilarity of the fecal metagenomes. (D) Shannon diversity in the gut microbiome based on species composition. (E - H) Spearman correlation calculated between fecal calprotectin level (log) and the first axes of microbiome variation for species (E), metabolic pathways (F), enzymes (G) and Shannon diversity (H). Colors represent the different IBD phenotypes (UC, CD, Normal pouch and Pouchitis), as well as

22

912 healthy subjects (Control) study groups. *P < 0.05; **P < 0.01; ***P < 0.001; Kruskal-Wallis, applying
 914 Dunn's multiple correction test. For the list of all pairwise P-values see Supplementary Table 2.
 916 Boxplot whiskers mark observations within the 1.5 interquartile range of the upper and lower quartiles.



956

Fig. 2 Bacterial species associated with IBD phenotypes. A generalized linear mixed-effects model was built for each bacterial species, and IBD phenotypes were set as a predictor (including age and antibiotic use as fixed effects). Healthy subjects were used as a reference point, and individual subjects and cohort were set as random effects. Only species with a mean relative abundance across all groups $\geq 0.15\%$ with a least one significant association with an IBD phenotype are presented. For the full list of species that were significantly associated with IBD phenotypes see Supplementary Table 2. Asterisks indicate patient groups for which the association was significant (FDR < 0.05).




Fig. 3 Mucin degradation potential of the microbiome of patients with IBD and healthy controls. **(A)** Bacterial community mucin degradation potential based on analysis of glycoside hydrolase genes (GH) that are involved in the breakdown and utilization of mucin-derived glycans. **(B, C)** Contribution of glycoside hydrolase enzymes Alpha-L-fucosidase and Exo-alpha-sialidase by bacterial genera. Each bar on the x-axis represents a sample from the corresponding phenotype (color coded) and the y-axis is the log-scaled total community gene abundance (sum-normalized to copies per million [cpm] units). The contributions of the top genera are proportionally scaled within the total, see the legend at the bottom of the figure **(D - F)** The relative fraction of *Ruminococcus gnavus* strains encoding strain-specific glycoside hydrolases (normalized according to three single-copy housekeeping genes) involved in mucin degradation; GH29 Alpha-L-fucosidase **(D)**, GH95 glycoside hydrolase family 95 **(E)** and GH33 Exo-alpha-sialidase **(F)**. *P < 0.05; **P < 0.01; ***P < 0.001; Kruskal-Wallis, applying Dunn's multiple correction test. For the list of all pairwise P-values see Supplementary Table 2. Boxplot whiskers mark observations within the 1.5 interquartile range of the upper and lower quartiles.





Fig. 4 The main pathways of microbial butyrate synthesis in IBD and healthy subjects. Modeling and quantification of the terminal genes (*but*, *buk*, *ato* and *4hbt*) for corresponding butyrate synthesis pathways in the metagenomes: (A, E) butyryl-CoA:acetate CoA transferase (*but*); (B, F) butyrate kinase (*buk*) - acetyl-CoA and glutarate pathways; (C, G) butyryl-CoA:acetoacetate CoA transferase (*ato*) - lysine pathway; (D, H) butyryl-CoA:4-hydroxybutyrate CoA transferase (*4hbt*) - 4-aminobutyrate pathway. In A-D, linear model coefficients (effect sizes) are given for each phenotype for the modeled genes. *P < 0.05; **P < 0.01; ***P < 0.001. In E-H, gene abundance is in RPKM units (reads per kilobase per million mapped reads), normalized according to the corresponding median gene

length and total-sum scaled to the number of reads in each metagenome. *P < 0.05; **P < 0.01; ***P < 0.001; Kruskal-Wallis, applying Dunn's multiple correction test. For the list of all pairwise P-values see Supplementary Table 2. Boxplot whiskers mark observations within the 1.5 interquartile range of the upper and lower quartiles.

998



1000 **Fig. 5** Secondary bile acids (DCA and LCA) formation potential in the metagenomes of patients with
1001 IBD and healthy subjects. The *bai* genes cluster (*baiA-I* operon) was quantified in the metagenomes.
1002 (A) Linear model coefficients (effect sizes) are given for each phenotype for the modeled *bai* genes
1003 cluster. *P < 0.05 (B) Gene abundance is in RPKM units (see legend of Fig. 4). *P < 0.05, **P < 0.01;
1004 *P < 0.01; Kruskal-Wallis, applying Dunn's multiple correction test. For the list of all pairwise P-
1005 values see Supplementary Table 2. Boxplot whiskers mark observations within the 1.5 interquartile
1006 range of the upper and lower quartiles.

1008

1010

1012

1014

1016

1018


1020

1022

1024

1026

1028



Diagnosis metadata:

- a_Control
- b_UC
- c_CD
- d_Normal_pouch
- e_Pouchitis

Microbial enzymes contributors:


- | | | | | |
|--|---|--|---|---|
| ■ <i>Escherichia</i> | ■ <i>Streptococcus</i> | ■ <i>Bifidobacterium</i> | ■ <i>Prevotella</i> | ■ <i>Faecalibacterium</i> |
| ■ <i>Klebsiella</i> | ■ <i>Lactobacillus</i> | ■ <i>Actinomyces</i> | ■ <i>Bacteroides</i> | ■ <i>Clostridium</i> |
| ■ <i>Citrobacter</i> | ■ <i>Pediococcus</i> | ■ <i>Eggerthella</i> | ■ <i>Parabacteroides</i> | ■ <i>Coprococcus</i> |
| ■ <i>Morganella</i> | ■ <i>Lactococcus</i> | ■ <i>Veillonella</i> | ■ <i>Alistipes</i> | ■ <i>Dorea</i> |
| ■ <i>Proteus</i> | ■ <i>Weissella</i> | ■ <i>Dialister</i> | | |
| ■ <i>Haemophilus</i> | ■ <i>Leuconostoc</i> | ■ <i>Akkermansia</i> | | |
| ■ Other | ■ <i>Enterococcus</i> | | | |

1030

1032

1034


1036 **Fig. 6** Enzymes related to protection against oxidative stress and the bacteria encoding them in the
 1038 metagenomes of patients with IBD and healthy subjects. Six such enzymes were identified and
 1040 quantified; **(A)** glutamate-cysteine ligase, **(B)** glutathione synthase, **(C)** glutathione-disulfide reductase,
 1042 **(D)** superoxide dismutase, **(E)** peroxiredoxin and **(F)** peptide-methionine sulfoxide reductase. Each bar
 1044 on the x-axis represents a sample from the corresponding phenotype (color coded) and the y-axis is log-
 1046 scaled total community gene abundance (sum-normalized to copies per million [cpm] units). The
 1048 contributions of the top genera are proportionally scaled within the total, “Other” encompasses
 1050 contributions from additional lower abundance genera, see the legend at the bottom of the figure.



1076 **Fig. 7** Total oxidative stress response in the microbiome. **(A)** Oxidative stress response enzymes (from
 1078 Fig. 6) associated with IBD phenotypes. A generalized linear mixed-effects model was built for each
 1080 gene, and IBD phenotypes were set as a predictor (see legend of Fig. 2). Asterisks indicate patient
 groups for which the association was significant (FDR < 0.2). **(B)** The combined contribution of these
 six oxidative stress response enzymes in metagenomes of patients with IBD and healthy subjects. *P <
 0.05; **P < 0.01; ***P < 0.001; Kruskal-Wallis, applying Dunn’s multiple correction test. For the list


of all pairwise P-values see Supplementary Table 2. Boxplot whiskers mark observations within the 1.5
 1082 interquartile range of the upper and lower quartiles.

1084



1086 **Fig. 8** Classification models to distinguish between patients with a normal pouch and pouchitis. We
 1088 trained and evaluated gradient boosting trees (GBT) classifiers on bacterial composition, metabolic
 1089 pathways and enzymes profiles from the metagenomes of patients with a pouch (discovery cohort) by
 1090 using five-fold cross-validation (randomly repeated 100 times). Area under the curve (AUC) measure
 1091 (mean \pm standard deviation) of each classifier performance is presented. (A) Species based classifier.
 1092 (B) Metabolic pathways-based classifier. (C) Enzymes-based classifier. (D) Fecal calprotectin-based
 1094 classifier. For each different classifier (species-, pathways- and enzymes- based, except for calprotectin
 only), three different models were built, with a full set of features (purple), reduced set with k=top
 scoring features and with a reduced set of features and fecal calprotectin as an additional predictor.

1096 **Supplementary figures**



1098 **Supplementary Fig. 1** The microbiome variation (principal coordinates analysis, PCoA) based on
 1100 Bray-Curtis dissimilarity for (A) species, (B) pathways and (C) enzymes compositional profiles of the
 1102 fecal metagenomes. (D) Variables explaining the variation in microbiome species, pathways and
 enzymes, analyzed with PERMANOVA. Percentages indicate variance explained by each variable (R²
 values) independently of the other variables. *P < 0.05; **P < 0.01; ***P < 0.001.

1104

1106

1108


1110

1112


1114

1116

1118
1120
1122
1124
1126
1128
1130
1132
1134
1136



Supplementary Fig. 2 Fecal calprotectin levels (log-transformed) in patients with IBD and healthy controls. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; Kruskal-Wallis, applying Dunn's multiple correction test. For the list of all pairwise P-values see Supplementary Table 2. Boxplot whiskers mark observations within the 1.5 interquartile range of the upper and lower quartiles. Fecal calprotectin measurements were available for 358 out of 428 samples (see Supplementary Table 1).




1138
1140
1142

Supplementary Fig. 3 Comparison of 15 publicly available pouch metagenomes from an American cohort (³¹Sinha et al. 2020) to the rest of the pouch and non-pouch metagenomes analysed in the current study. (A) The microbiome variation according to the first axes of principal coordinates analysis (PCoA) of species profiles, based on Bray-Curtis dissimilarity of the fecal metagenomes. (B) Shannon diversity in the microbiome based on species composition. (C) PCoA analysis of species profiles based


1144 on Bray-Curtis dissimilarity of the fecal metagenomes. The samples labeled as “Pouch” are the pouch metagenomes from ³¹Sinha et al. 2020.

1146



1148 **Supplementary Fig. 4** The Major butyrate producers in the fecal metagenomes of patients with IBD
1150 and healthy controls. The relative fraction and taxonomic affiliation of the most abundant butyrate-
1152 producing bacteria based on the similarity of the identified *but* (butyryl-CoA:acetate CoA transferase)
and *buk* (butyrate kinase) genes to known butyrate producers. *Coprococcus comes*, *Subdoligranulum*
variabile and *Clostridium perfringens* were quantified based on *but*, and the rest of the species based on
but. For a complete list of all the identified butyrate producers, see Supplementary Table 4

1154



1156 **Supplementary Fig. 5** Spearman correlation between the abundance of butyrate synthesis genes (*but*,
1157 *buk*, *ato* and *4hbt*) and fecal calprotectin levels in patients with IBD and healthy controls. Fecal
1158 calprotectin measurements were available for 358 out of 428 samples (see Supplementary Table 1).

1160

1162


1164

1166

1168

1170

1172




1174 **Supplementary Fig. 6** Spearman correlation between the abundance of secondary bile acids formation
 1176 genes, *bai* (*baiA-I* operon) and fecal calprotectin levels in patients with IBD and healthy controls. Fecal
 1178 calprotectin measurements were available for 358 out of 428 samples (see Supplementary Table 1).

1178



1180

1182



1184 **Supplementary Fig. 7** Highest scoring species features (most informative for classification) used in
 1186 the classification model (of Fig. 8A) to distinguish between patients with a normal pouch and pouchitis.
 1188 The average importance scores for the top 40 features are displayed, divided into “potentially beneficial
 bacteria”, “potential pathobiont / oral bacteria” and “unknown commensals” based on recent literature
 consensus. For the full list of scores for each species, see Supplementary Table 6.

1188



1190 **Supplementary Fig. 8** Testing the model performance (best species-based with k=40 top features)
1191 trained on the discovery cohort (n=208 samples) in classifying samples from the validation cohort
1192 (n=42 samples) with recurrent-acute pouchitis phenotype, into a normal pouch or pouchitis according
1193 to the last observed phenotype (by future clinical observation). **(A)** Area under the curve (AUC)
1194 measure of two classifiers (with or without calprotectin as an additional predictor) **(B)** Confusion
1195 matrix evaluation of the classifier (with calprotectin), comparing the number of correctly and
1196 incorrectly classified samples. 24/27 recurrent-acute samples that later changed to pouchitis and 8/15
1197 that later changed to a normal pouch, were classified correctly, respectively.
1198

1200 **Supplementary methods**

Pouch Disease Behavior (pouch phenotype)

1202 Pouch disease behavior was defined as normal, acute/recurrent-acute pouchitis, chronic pouchitis, or
1203 CLDP, as previously defined [1]. Briefly, a normal pouch was defined as no symptoms of pouchitis
1204 during the past 2 years and no antibiotic therapy. Acute/recurrent-acute pouchitis was defined as a flare
1205 of pouchitis responding to a short course (usually 2 weeks) of antibiotic therapy, or up to 4 flares/year,
1206 respectively. Chronic pouchitis was defined as >4 pouchitis flares/year or administration of antibiotics
1207 or IBD-specific anti-inflammatory therapy for more than 1 month. CLDP was defined as having pouch-
1208 perianal disease, pouch strictures, or long segments of proximal small intestinal inflammation. Patients
1209 undergoing pouch surgery due to familial adenomatous polyposis (FAP) were recruited as well and had
1210 a normal pouch throughout follow-up.

Dietary information based on food frequency questionnaires

1212 Intake of food groups and nutrients were assessed using Food Frequency Questionnaires (FFQs)
1213 adapted to the Israeli population and administered in "MABAT" Israeli nutrition and public health
1214 governmental study [2]. For each of the 106 food items, a commonly used portion size was specified.
1215 Patients were asked how often on average they consumed each food item and daily intake of nutrients
1216 was calculated by multiplying the frequency of each food item by the nutrient content based on the
1217 Israeli TZAMERET food database and the United States Department of Agriculture (USDA) food
1218 database [3].
1219

Supplementary references

- 1222 1. Tulchinsky, H. et al. Comprehensive pouch clinic concept for follow-up of patients after ileal pouch
1223 anal anastomosis: Report of 3 years' experience in a tertiary referral center: Inflammatory Bowel
1224 Diseases 14, 1125–1132 (2008).
- 1225 2. Kaluski DN, Goldsmith R, Arie OMB, et al (2000) The first Israeli national health and nutrition
1226 survey (MABAT) as a policy maker. In: Public Health Reviews. Pp 23–26
- 1227 3. Montville JB, Ahuja JKC, Martin CL, et al (2013) USDA Food and Nutrient Database for
1228 Dietary Studies (FNDDS), 5.0. *Procedia Food Sci* 2:99–112.